Press Releases Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
4,765 ^KRW	+0.42%		+0.95%	-2.76%

Mar. 20	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma: increase in number of shares and votes	May. 03	AQ
Hansa Biopharma interim report January-March 2024	Apr. 18	AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	Apr. 11	AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	Apr. 02	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	Mar. 21	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	Feb. 22	AQ
Hansa Biopharma Year-end report January-December 2023	Feb. 02	AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	Jan. 06	AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	Dec. 15	AQ
Hansa Biopharma Nomination Committee formed	Dec. 13	AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	Dec. 08	AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	Dec. 05	AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	Nov. 27	AQ
Hansa Biopharma Interim Report January-September 2023	23-10-26	AQ
Hansa Biopharma - Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	23-10-18	AQ
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	23-10-17	AQ
Hansa Biopharma - Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	23-10-12	AQ
Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	23-10-11	AQ
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487	23-10-09	AQ
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	23-09-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

Press Releases

Filters